Glaukos Corp(GKOS) Finding the best opportunities to buy and sell stocks daily.

Sector:

Healthcare

Description:

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite for use as a standalone procedure in patients with refractory glaucoma; iStent SA, a two-stent product that is designed for use as a standalone glaucoma procedure; iDose Travoprost, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication; and MicroShunt, an ab-externo device for treatment of open-angle glaucoma. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was founded in 1998 and is headquartered in San Clemente, California.

Current Price

$83.04

RSI

17.316

Beta:

1.686707

March 01, 2021
96.6M
270.8M
8.5M

11.215 %
-6.407 %
52.526 %
-133.795 %

$224,959,000
$236,984,000
$181,278,000
$159,254,000
$114,397,000
$71,700,000
-5.345 %
30.730 %
13.829 %
39.212 %
59.550 %

$-132,314,000
$-50,036,000
$-12,368,000
$1,000
$4,565,000
$-38,288,000
-62.184 %
-75.282 %
-100.008 %
-456400.000 %
938.729 %

News

Press Releases

Notable Dates

All stock recommendations and comments are all opinions. Investors should be cautious about any and all stock recommendations and should consider the source of any advice on stock selection. Various factors, including personal ownership, may influence or factor into a stock analysis or opinion. All investors are advised to conduct their own independent research into individual stocks before making a purchase decision. In addition, investors are advised that past stock performance is not indicative of future price action.